标准抗结核治疗方案对耐多药肺结核患者肾功能的影响分析

doi:10.19871/j.cnki.xfcrbzz.2022.03.007

新发传染病电子杂志 ›› 2022, Vol. 7 ›› Issue (3): 32-36.doi: 10.19871/j.cnki.xfcrbzz.2022.03.007

标准抗结核治疗方案对耐多药肺结核患者肾功能的影响分析

付寒¹, 王鹏¹, 张宗华¹, 季乐财²

1. 深圳市慢性病防治中心药剂科,广东深圳 518020;
2. 深圳市慢性病防治中心结核病科,广东深圳 518020

收稿日期:2022-01-16 出版日期:2022-07-31 发布日期:2022-09-08
通讯作者: 季乐财,Email：jilecai@foxmail.com
基金资助:
广东省医学科研基金（B2021075）

Analysis of the effect of standard anti-TB treatment regimen on renal function in patients with MDR-TB

Fu Han¹, Wang Peng¹, Zhang Zonghua¹, Ji Lecai²

1. Department of Pharmacy, Shenzhen Center for Chronic Disease Control, Guangdong Shenzhen 518020,China;
2. Department of Tuberculosis, Shenzhen Center for Chronic Disease Control, Guangdong Shenzhen 518020, China

Received:2022-01-16 Online:2022-07-31 Published:2022-09-08

摘要/Abstract

摘要： 目的分析耐多药肺结核（MDR-TB）患者采用标准抗结核方案治疗过程中药物对肾功能的损伤程度,并评价其对治疗的影响。方法采用回顾性调查的方法,收集2018年1月至2019年12月在深圳市慢性病防治中心结核病科治疗的125例MDR-TB患者的临床资料和检验数据,分析患者血清肌酐、尿素及尿蛋白等检测指标的变化情况,应用R软件（3.6.2版本）进行统计处理并绘图。结果 125例患者治疗方案中包括阿米卡星等注射剂占81.6%（102/125）,不包括注射剂为18.4%（23/125）。102例包含注射剂方案出现肾功能异常24例,23例不包含注射剂出现肾功能异常8例(χ2=1.506,P=0.220)。在治疗过程中,25.6%（32/125）的患者出现不同类型肾功能检测指标异常：单纯尿素升高患者占8.0%（10/125）,单纯血肌酐升高患者占5.6%（7/125）,单纯尿蛋白阳性者3.2%（4/125）,尿素合并血肌酐升高者5.6%（7/125）,尿素升高合并尿蛋白阳性者1.6%（2/125）,血肌酐升高合并尿蛋白阳性者0.8%（1/125）,三者均异常者0.8%（1/125）。尿蛋白出现阳性时间早于尿素、血肌酐升高时间。参考RIFLE诊断分级标准,有2.4%（3/125）患者出现肾功能损害。结论标准抗结核方案在治疗MDR-TB过程中对患者的肾功能影响较小,患者肾功能异常多为一过性轻微异常,阿米卡星等注射剂也并未造成患者肾功能损伤显著增加。在治疗过程中及时监测尿常规、肾功能,特别是尿蛋白,及早发现异常、妥善处理,能有效避免严重的肾损伤发生,保证治疗方案的有效实施。

关键词: 耐多药肺结核, 肾功能, 抗结核治疗方案, 药物不良反应

Abstract: Objective To explore the extent of drug damage to renal function during the treatment of MDR-TB patients with a standard anti-TB regimen, and evaluate its impact on the treatment. Method The clinical data and test data of 125 MDR-TB patients treated in the Tuberculosis Department of Shenzhen Chronic Disease Prevention and Treatment Center from January 1, 2018 to December 31, 2019 were collected retrospectively, and the changes of serum creatinine, urea nitrogen and urine protein were analyzed. R software (version 3.6.2) was used for statistical processing and drawing. Result Among 125 patients, 81.6% (102/125) included injections such as amikacin in their treatment regimen, and 18.4% (23/125) did not. There were 24 patients with abnormal renal function in 102 patients with injection regimen, and 8 patients with abnormal renal function in 23 patients without injection regimen. The value of χ2 was 1.506, P=0.220. During the course of treatment, 25.6% (32/125) patients showed abnormal renal function indicators of different types: 8.0% (10/125) patients with increased urea alone, 5.6% (7/125) patients with increased serum creatinine alone, 3.2% (4/125) patients with positive urine protein alone, and 5.6%( 7/125) patients with increased urea combined with increased serum creatinine, 1.6% (2/125) patients with increased urea combined with positive urinary protein, patients with elevated serum creatinine combined with positive urinary protein were 0.8% (1/125), and those with all three abnormalities were 0.8% (1/125). The positive time of urine protein is earlier than that of urea and creatinine. According to RIFLE's diagnostic scale, 2.4% (3/125) of patients had renal impairment. Conclusion The Standard anti-tuberculosis regimen had little effect on patients' renal function during the treatment of MDR-TB, and most of the patients had transient mild abnormalities. Amikacin injection did not cause significant increase in renal injury. In the course of treatment, timely monitoring of routine urine and renal function, especially urinary protein, early detection of abnormalities and proper treatment can effectively avoid the occurrence of serious kidney injury and ensure the effective implementation of treatment regimen.

Key words: Multidrug-resistant pulmonary tuberculosis, Renal function, Anti-TB treatment regimen, Adverse drug reactions

付寒, 王鹏, 张宗华, 季乐财. 标准抗结核治疗方案对耐多药肺结核患者肾功能的影响分析[J]. 新发传染病电子杂志, 2022, 7(3): 32-36.

Fu Han, Wang Peng, Zhang Zonghua, Ji Lecai. Analysis of the effect of standard anti-TB treatment regimen on renal function in patients with MDR-TB[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(3): 32-36.

参考文献

[1] 郑梅琴, 刘硕, 许瑞, 等. 国家组织药品集中采购对耐药结核病患者药物可负担性的影响[J]. 中国药业, 2022, 31(1):8-11.
[2] 卢春容,房宏霞,陆普选,等. 2021 WHO全球结核病报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志,2021,6(4):368-372.
[3] 聂理会, 初乃惠.《耐药结核病规划管理指南2011年更新版》解读[J]. 中国临床医生 2013, 41(3): 6-8.
[4] 初乃惠. 积极推进耐药结核病全口服短程治疗方案的实施[J]. 中国临床医生杂志, 2020, 48(12):1387-1389.
[5] 刘怡, 李燕芬, 沈晓君, 等. 抗结核药物使用引起患者肾功能损害的分析与护理[J]. 中国医药导报, 2014, 11(2):150-152.
[6] WORLD HEALTH ORGANIZATION.WHO treatment guidelines for drug-resistant tuberculosis[R]. Geneva:World Health Organization, 2016.
[7] BELLOMO R, RONCO C, KELLUM JA, et al.Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group[J]. Crit Care, 2004, 8(4): R204-212.
[8] 中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10):1025-1073.
[9] 王国杰. 耐多药肺结核患者抗结核药物不良反应分析[J]. 现代医药卫生, 2019, 35(24):3821-3823.
[10] WORLD HEALTH ORGANIZATION.Companion handbook to the WHO guidelines for the programmatic management of drug¬resistant tuberculosis[R]. Geneva: World Health Organization, 2014.
[11] WORLD HEALTH ORGANIZATION.WHO treatment guidelines for multidrugand rifampicin-resistant tuberculosis[R].Geneva: World Health Organization, 2018.
[12] WORLD HEALTH ORGANIZATION.WHO consolidated guidelines on drug-resistant tuberculosis treatment.Geneva: World Health Organization, 2019.
[13] 周文强, 初乃惠. 耐药结核病治疗的进展[J].中国临床医生杂志, 2020, 48(12):1396-1399.
[14] 刘群群, 苗艳芳. 耐多药肺结核88例抗结核药物不良反应发生情况分析[J]. 中国药物与临床, 2015, 15(5):730-732.
[15] 王玉洲. 抗结核药致肾功能损害发生机制及防治对策[C], 全国抗结核治疗的不良反应及处理学术会议论文汇编, 2001.
[16] 杨梁梓,任坦坦,傅向东,等.含贝达喹啉新方案治疗耐药肺结核的疗效与安全性研究[J/CD].新发传染病电子杂志,2021,6(4):302-305.
[17] WU H, HUANG J.Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies[J]. Curr Drug Metab, 2018, 19(7): 559-567.
[18] WORLD HEALTH ORGANIZATION.Multidrug and extensively drug-resistant TB(M/XDR-TB)-2010 global report on surveillance and response[R].Geneva: World Health Organization, 2010.
[19] AHMAD N, JAVAID A, SYED SULAIMAN SA, et al.Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients[J]. Am J Ther, 2018, 25(5): e533-e540.
[20] SHIBESHI W, SHETH AN, ADMASU A, et al.Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study[J]. BMC Pharmacol Toxicol, 2019, 20(1):20-31.
[21] 陈心春,温志华.基于宿主基因定向治疗耐多药结核病:机遇与挑战[J/CD].新发传染病电子杂志, 2017, 2(3):129-132.

标准抗结核治疗方案对耐多药肺结核患者肾功能的影响分析

Analysis of the effect of standard anti-TB treatment regimen on renal function in patients with MDR-TB

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价